Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLUVAL AB Novo immunogenicity and tolerability study in children and adolescents
2013-003449-40Phase 3Completed
- Sponsor
- Omninvest
- Start
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, single-arm trial of Fluval AB Novo in influenza, sponsored by Omninvest. Primary endpoint: Immunogenicity by hemagglutination inhibition test. Started Aug 2013; status: completed.
02
Drugs
Fluval AB Novo
03
Conditions
influenza
Beyond the preview
Go deeper on 2013-003449-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-003449-40.